Rolling review begins based on lab and clinical studies in adults
News
Chancellor pledges an extra £1.65bn for UK’s COVID-19 vaccination roll-out
Budget 2021 also details new funding for UK life sciences companies and more
ERS Genomics signs CRISPR license agreement with Otsuka
License grants Otsuka access to CRISPR/Cas9 genome editing technology
Idorsia submits investigational insomnia treatment daridorexant to the EMA
Daridorexant is a dual orexin receptor agonist (DORA) designed for the treatment of insomnia
US court rules in favour of AZ in Symbicort patent litigation
Court decision rules against Mylan Pharmaceuticals and Kindeva Drug Delivery
NICE backs NHS use of Lilly’s Olumiant in eczema
Oral JAK inhibitor approved to treat moderate-to-severe atopic eczema in adults
Cosentyx gains EU approval for new label extension
Label update includes data for axial manifestations of psoriatic arthritis
NHS prescription charges set to rise in England
Charge will increase to £9.35 per single prescription item from 1 April 2021
NICE backs selective internal radiation therapy for advanced liver cancer
Hundreds of people will be able to benefit from this treatment type
Cancer Research UK teams up with Teon on new cancer drug
Focus of the agreement is a first-in-class small molecule adenosine A2B receptor antagonist
Genomics plc scores $30m to expand patient-centric health platform
Latest funding round includes investments from Foresite Capital and F-Prime Capital
Tribunal upholds CMA’s decision to fine Lexon £1.2m
Company found to have broken competition law to drive up prices of antidepressant nortriptyline
FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A
First therapy approved for the ultra-rare and progressive condition
Evrysdi leads latest CHMP recommendations
The Committee has recommended six medicines for approval at its February 2021 meeting
Wayra, GE Healthcare launch accelerator programme for digital health start-ups
Edison Accelerator to support start-ups to develop AI applications for healthcare
